Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States...

Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United
States and Canada

BURLINGTON, Mass., May 11 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of
light-based systems for cosmetic treatments, announced today that it has
entered into a Distribution Agreement with Quantel SA (Euronext: QUA), a
leading manufacturer of solid state lasers, for Quantel's SINON(TM) Q-switched
ruby laser system for tattoo removal in the United States and Canada.

The SINON Q-switched ruby laser was developed by Quantel Derma GmbH (formerly
WaveLight Aesthetic GmbH) based in Erlangen, Germany. Its speed and clinical
efficacy make the SINON the choice of leading experts in aesthetic dermatology
for tattoo removal. The SINON(TM) Q-switched ruby laser will be exclusively
marketed by Palomar in the United States and Canada. Quantel Derma USA based
in Bozeman, Montana will be in charge of installation and technical support of
the systems.

Chief Executive Officer Joseph P. Caruso commented, "We are pleased to become
the exclusive distributor for Quantel Derma's SINON Q-Switched ruby laser for
tattoo removal in the United States and Canada. With the shortest pulse and
highest peak power of all ruby lasers available, the SINON ruby laser is
optimized to treat the more complex and difficult to remove tattoos you see
today."

Alain de Salaberry, Quantel's President Director General said, "Its strong
sales force and its experience with Q-switch ruby lasers make Palomar an ideal
partner for the marketing of Quantel's SINON system."

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and
developer of light-based systems for cosmetic treatments. Palomar pioneered
the optical hair removal field, when, in 1997, it introduced the first
high-powered laser hair removal system. Since then, many of the major advances
in light-based hair removal have been based on Palomar technology. In December
2006, Palomar became the first company to receive a 510(k) over-the-counter
(OTC) clearance from the United States Food and Drug Administration (FDA) for
a new, patented, home use, light-based hair removal device. OTC clearance
allows the product to be marketed and sold directly to consumers without a
prescription. There are now millions of light-based cosmetic procedures
performed around the world every year in physician offices, clinics, spas and
salons. Palomar is testing many new and exciting applications to further
advance the hair removal market and other cosmetic applications. Palomar is
focused on developing proprietary light-based technology for introduction to
the mass markets. Palomar has granted The Procter & Gamble Company a
non-exclusive License Agreement to certain patents, technology and FDA
documents related to the home-use, light-based hair removal field for women.
In addition, Palomar has an exclusive development and license agreement with
Johnson & Johnson Consumer Companies to develop and potentially commercialize
home-use, light-based devices for reducing or reshaping body fat including
cellulite, reducing the appearance of skin aging, and reducing or preventing
acne.

About The Quantel Group: Founded in 1970, the QUANTEL Group has over the last
10 years established itself as one of the world's leading specialists for
scientific (research laboratories, universities), industrial (micromachining,
metrics, military) and medical (ophthalmology, dermatology) laser
technologies.

This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based on the Company's current expectations, plans, intentions,
beliefs or predictions. These forward-looking statements are neither promises
nor guarantees, but involve risk and uncertainties that may individually or
mutually impact the matters herein, and cause actual results, events and
performance to differ materially from such forward-looking statements. These
risk factors include, but are not limited to, results of future operations,
technological difficulties in developing or introducing new products, the
results of future research, lack of product demand and market acceptance for
current and future products, the effect of economic conditions, challenges in
managing joint ventures and research with third parties and government
contracts, the impact of competitive products and pricing, governmental
regulations with respect to medical devices, including whether FDA clearance
will be obtained for future products and additional applications, the results
of litigation, including patent infringement lawsuits, difficulties in
collecting royalties, potential infringement of third-party intellectual
property rights, factors affecting the Company's future income and resulting
ability to utilize its NOLs, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on Form 10-K
for the year ended December 31, 2008 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. The
Company undertakes no obligation to release publicly the result of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

Contacts:
Kayla Castle Sanford Lane
Investor Relations Manager Chief Executive Officer
Palomar Medical Technologies, Inc. Quantel Derma USA, Inc.
781-993-2411 508-654-0310
kcastle@palomarmedical.com SLane@quantelmedical.com

SOURCE Palomar Medical Technologies, Inc.

Kayla Castle, Investor Relations Manager of Palomar Medical Technologies,
Inc., +1-781-993-2411, kcastle@palomarmedical.com; Sanford Lane, Chief
Executive Officer of Quantel Derma USA, Inc., +1-508-654-0310,
SLane@quantelmedical.com